ArticleJournal of cellular and molecular medicine2026
Salvianolic Acid B Inhibited LH2 Expression to Reduce Collagen Synthesis in Pulmonary Fibrosis.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Collagen deposition and scar formation are hallmark features of fibrotic diseases. Lysyl hydroxylase 2 (PLOD2/LH2), a key collagen-modifying enzyme, catalyses lysine hydroxylation at telopeptide sites to promote pyridinoline cross-link formation, thereby enhancing collagen stability and matrix stiffness. However, the mechanisms regulating LH2 in pulmonary fibrosis (PF) are not fully understood. Here, we identify Salvianolic acid B (SAB) as a potent antifibrotic compound that targets LH2-associated collagen cross-linking. LH2 expression was markedly increased in alveolar epithelial cells and fibroblasts during PF, and its silencing attenuated TGF-β1-induced fibrotic protein expression. SAB reduced LH2 protein levels and significantly alleviated fibrotic remodelling, as evidenced by restored lung architecture and reduced collagen deposition. Mechanistically, the antifibrotic effects of SAB and LH2 were associated with inhibition of epithelial-mesenchymal transition (EMT), fibroblast-to-myofibroblast transition (FMT), and the Wnt/β-catenin signalling pathway. This study indicates that pharmacological inhibition of LH2 by SAB effectively disrupts collagen cross-linking and fibrotic progression, offering a promising therapeutic avenue for pulmonary fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.